Strong correlation between results of fluorescent In situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma

Modern Pathology

Volumn 13, Issue 11, 2000, Pages 1238-1243

  Couturier, Jérôme ^a   Vincent Salomon, Anne ^a   Nicolas, André ^a   Beuzeboc, Philippe ^a   Mouret, Emmanuelle ^a   Zafrani, Brigitte ^a   Sastre Garau, Xavier ^a  

^a INSTITUT CURIE   (France)

Author keywords

Breast carcinoma; C erbB2; ERBB2; Fluorescent in situ hybridization (FISH); HER 2 neu; Immunohistochemistry; Node negative

Indexed keywords

ARTICLE; BREAST CARCINOMA; CLINICAL ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE SECTION;

EID: 0033724898     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880228     Document Type: Article

References (35)

1. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
2. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
3. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group
4. Prognostic significance of HER-2/neu oncoprotein expression in node- positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy
5. The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases
6. ERBB2 Oncogene in human breast cancer and its clinical significance
7. HER-2/neu (c-erbB-2) gene and protein in breast cancer
8. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
9. p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer
10. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
11. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
12. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer
13. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
14. ERBB2 overexpression in breast carcinomas: No positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy
15. Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis
16. Her-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
17. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
18. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
19. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
20. Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu
21. Quantitative PCR analysis of c-erb-B-2 (HER2/neu) gene amplification and comparison with p185(HER2/neu) protein expression in breast cancer drill biopsies
22. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
23. Sensitivity of Her-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
24. c-erbB-2 amplification in breast cancer: Detection in formalin-fixed, paraffin-embedded tissue by in situ hybridization
25. Detection and quantification of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
26. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization
27. The combination of in situ hybridization and immunohistochemical analysis: An evaluation of Her2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium
28. c-erbB-2 over-expression in amplified and non-amplified breast carcinoma samples
29. Comparison of fluorescence in situ hybridization and immunohistochemistry for evaluation of HER-2/neu in breast cancer
30. Detection and quantification by FISH and image analysis of Her-2/neu amplification in breast cancer fine-needle samples
31. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates
32. Determination of Her-2/Neu status in breast carcinoma: Comparative analysis of immunohistochemistry and fluorescent in situ hybridization
33. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drugs Administration-approved scoring system
34. Increased HER2 with U. S. Food and Drug Administration-approved antibody
35. Detection of DNA amplification in 17 primary breast carcinomas with homogeneously staining regions by a modified comparative genomic hybridization technique